LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

J.P. Cebrià-Costa[1], L. Pascual-Reguant[1], A. Gonzalez-Perez[2], G. Serra-Bardenys[1], J. Querol[1], M. Cosín[1], G. Verde[3], R.A. Cigliano[4], W. Sanseverino[4], S. Segura-Bayona[2], A. Iturbide[5], D. Andreu[6], P. Nuciforo[1], C. Bernado-Morales[1,7], V. Rodilla[1], J. Arribas[1,7,8,9], J. Yelamos[10], A. Garcia de Herreros[6,10], T.H. Stracker,[2] S. Peiró[1*]

[1]Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. [2]Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028 Barcelona, Spain. [3]Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain. [4]Sequentia Biotech SL, Comte d'Urgell, 240, Barcelona, Spain. [5]Institute of Epigenetics and Stem Cells, Helmoholtz Zentrum München, D-81377 München, Germany. [6]Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. [7]Centro de Investigación Biomédica en Red en Oncología (CIBERONC), 08035 Barcelona, Spain. [8]Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain. [9]Departament de Bioquímica y Biología Molecular, Universitat Autónoma de Barcelona, Bellaterra, Spain. [10]Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

*Corresponding author. Email: speiro@vhio.net; Vall d'Hebron Institute of Oncology, c/ Natzaret 115-117, 08035 Barcelona, Spain; phone: 34-932 543 450 (8683)

Figure legends

Supplementary Figure 1. Western blot with the indicated antibodies in 293 cells infected with GFP (MOCKGFP+), LOXL2-IRES-GFP (LOXL2GFP+), or LOXL2mut-IRES-GFP (LOXL2mutGFP+).

Supplementary Figure 2. Percentage of the indicated chromosome alterations per total number of cells in Control and LOXL2 KD conditions in two independent experiments, with a representative image of each condition. *$P < 0.05$.

Supplementary Figure 3. (**A**) Caspase-3 activation analyzed by Western blot with the indicated antibodies. Tubulin was used as a loading control. Intervening lanes were removed as indicated. (**B**) Heat map and gene ontology (GO) analysis of differentially expressed genes by RNA-seq in control and *LOXL2* knockdown samples.

Supplementary Table 1. List of the antibodies and working dilutions used in the manuscript.

Supplementary Table 2. List of the primers used in the manuscript.